- Home
- CFR vs ROIV Comparison
CFR vs ROIV Comparison
Compare CFR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | ROIV |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United Kingdom |
| Employees | 6008 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CFR | ROIV |
|---|---|---|
| Price | $135.72 | $26.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $143.08 | $27.56 |
| AVG Volume (30 Days) | 479.1K | ★ 4.6M |
| Earning Date | 04-30-2026 | 02-06-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $4.70 | $594.84 |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $100.31 | $8.73 |
| 52 Week High | $148.97 | $30.33 |
Technical Indicators
Market Signals| Indicator | CFR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 42.18 |
| Support Level | $134.54 | $20.46 |
| Resistance Level | $140.27 | $27.94 |
| Average True Range (ATR) | 2.76 | 0.88 |
| MACD | 0.49 | -0.38 |
| Stochastic Oscillator | 78.25 | 11.63 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of December 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.